Skip to main content
STIM
NASDAQ Industrial Applications And Services

Neuronetics Q2 Revenue Beats, But Going Concern Warning Clouds Outlook

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$3.182
Mkt Cap
$221.985M
52W Low
$0.8
52W High
$4.29
52W Position info
298% above low
Off High info
26% below high
Rel. Volume info
12× avg
Market data snapshot near publication time

STIM has more than doubled off its 52-week low of $0.8 on elevated volume (12× avg).

Summary

Neuronetics beat Q2 revenue estimates with $41.6 million and improved margins, but warned it may not survive as a going concern due to a projected debt covenant breach in March 2027.


Key Events · Earnings and Guidance · STIM

  • Going Concern Warning

    Substantial doubt exists about Neuronetics' ability to continue as a going concern. The company projects trailing twelve-month revenue through March 31, 2027 will be below the minimum required by its credit agreement, and it lacks the liquidity to repay the $65 million facility if called.

  • Q2 Revenue Beat, Margin Improvement

    Revenue of $41.6 million grew 9% year-over-year, beating estimates. Gross margin expanded to 51.1% from 46.6% a year ago, driven by higher-margin unlocked system sales and improved revenue cycle management.

  • Dilutive ATM Usage

    During Q2, Neuronetics sold 6.05 million shares under its at-the-market program at an average price of $1.31, raising $8.0 million in gross proceeds. $33.7 million remains available for future sales, representing potential further dilution.

  • Debt Covenant Amendment and Repayment

    In March 2026, the company amended its credit agreement to modify revenue and liquidity covenants and made a $5.0 million principal repayment, incurring a $0.5 million loss on partial debt extinguishment.


Analysis · STIM · Industrial Applications And Services

Neuronetics delivered Q2 revenue of $41.6 million, a 9% year-over-year increase that topped estimates, while gross margin climbed to 51.1%. Yet these operational gains are overshadowed by a stark warning: management has substantial doubt about the company's ability to continue as a going concern. The trigger is a projected shortfall in trailing twelve-month revenue through March 2027, which is expected to fall below the minimum required by its credit agreement. Should the lender demand repayment of the $65 million facility, Neuronetics lacks the liquidity to comply. During the quarter, the company sold 6.05 million shares under its ATM program at an average price of $1.31, raising $8 million in gross proceeds, but this dilutive issuance only adds to the concerns.

At the time of this filing, STIM was trading at $3.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $222M. The 52-week trading range was $0.80 to $4.29. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STIM - Latest Insights

STIM
Aug 11, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.50
Real-time Price: $3.19 info
Change: +$0.6901 (+28%) info
Market Cap: $221.985M info
STIM
Aug 11, 2026, 7:50 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.39
Real-time Price: $3.19 info
Change: +$0.798 (+33%) info
Market Cap: $221.985M info
STIM
Aug 04, 2026, 8:00 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $2.16
Real-time Price: $3.19 info
Change: +$1.03 (+48%) info
Market Cap: $221.985M info
STIM
Jul 20, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $3.19 info
Change: +$1.19 (+60%) info
Market Cap: $221.985M info
STIM
May 29, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.54
Real-time Price: $3.19 info
Change: +$1.65 (+107%) info
Market Cap: $221.985M info